Incentives for Influenza Vaccination

Influenza Vaccination Clinical Trial

Official title:

Financial Incentives for Influenza Vaccination

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06300242
• Other study ID #: UP-23-00859
• Status: Completed
• Phase: N/A
• Start date: January 17, 2024
• Est. completion date: February 29, 2024

Study information

• Verified date: May 2024
• Source: University of Southern California
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this work, we are assessing the impact of messaging with or without a $50 financial incentive on influenza vaccination rates in a county health system. Our main hypothesis is that a message with a $50 financial incentive will increase vaccination rates relative to a control/"treatment as usual" group. We further hypothesize that the financial incentive will increase vaccination rates relative to the message only arm.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69972
• Est. completion date: February 29, 2024
• Est. primary completion date: January 24, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ages 18 and over
• Empaneled patients or non-empaneled patients with a primary care visit in past 18 months with valid insurance
• Due for an annual flu shot according to the electronic medical record
• Active phone number or email
• Do not have "Do not contact" flag

Exclusion Criteria:

• Under age 18
• Received an annual flu shot based on medical record

Related Conditions & MeSH terms

• Influenza Vaccination
• Influenza, Human

Intervention

Behavioral:
• Reminders
Reminders
• Financial Incentive
$50 financial incentive for getting vaccinated within 1-week

Other:
• Placebo
No special messages or incentives

Locations

Country	Name	City	State
United States	Contra Costa Health Services	Martinez	California

Sponsors (2)

Lead Sponsor	Collaborator
University of Southern California	J-PAL North America

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vaccination status at 1 week	influenza vaccination status as documented in the EMR and from the California Immunization Registry (CAIRS)	1 week
Secondary	Vaccination status at 2 weeks	Influenza vaccination status as documented in the EMR and from the California Immunization Registry (CAIRS)	2 weeks
Secondary	Vaccination status at 1 month	Influenza vaccination status as documented in the EMR and from the California Immunization Registry (CAIRS)	1 month